II. Mechanism

  1. Conjugated protein Vaccine

III. Preparations

  1. Individual Vaccinations
    1. PRP-T (ActHIB or Hiberix)
    2. PRP-OMP (PedvaxHIB)
      1. Stronger immune response with first dose
      2. Preferred in high risk communities
        1. American Indian or Alaska native
        2. Asplenia or immunosuppression
  2. Standard Combination agents (most common delivery for U.S. Primary Series)
    1. DTaP/IPV/PRP-T (Pentacel)
    2. PRP-OMP/HepB (Comvax)
  3. Other combinations (limited use)
    1. Hib/MenCY (Menhibrix)

IV. Protocol: Primary Series

  1. Dose 1: Age 2 months
  2. Dose 2: Age 4 months
  3. Dose 3: Age 6 months (dose 3 is skipped if using PedvaxHIB for all other 3 doses)
  4. Dose 4: Age 12 to 15 months

V. Efficacy

  1. Decreased Incidence by 99% since Hib Vaccination began in 1989
    1. Previously Hib was most common cause of Meningitis and invasive disease <5 years old

VI. Adverse Effects

  1. No serious side effects
  2. Fever
  3. Irritability
  4. References
    1. (1996) MMWR Morb Mortal Wkly Rep 45(No. RR-12):1-35 [PubMed]

VII. Precautions: Immunocompromised State

  1. Immunocompromised state requires additional Hib doses (esp. if age 12 to 59 months)
    1. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#note-hib
  2. Conditions required additional Hib Vaccine doses (see CDC guidelines)
    1. Chemotherapy or Radiation Therapy
    2. Hematopoietic Stem Cell Transplant
    3. Anatomic Asplenia or Functional Asplenia (e.g. Sickle Cell Anemia)
    4. Elective Splenectomy
    5. HIV Infection
    6. Immunoglobulin Deficiency or Early component complement deficiency

VIII. Resources

  1. CDC Immunization Schedules (last accessed 10/28/2020)
    1. https://www.cdc.gov/vaccines/schedules/

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Haemophilus influenzae type b polysaccharide vaccine (C0062086)

Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH C044237
SnomedCT 333680004, 412374001
English Haemophilus influenzae type b polysaccharide vaccine, HIB-vaccine, HIB - Hemophilus influenzae Type B vaccine, HIB vaccine, Haemophilus influenzae Type b, Hemophilus influenzae Type b, Hemophilus influenzae Type b vaccine, Haemophilus influenzae type B vaccine, Haemophilus influenzae type b polyribosylribitol phosphate capsular polysaccharide vaccine, Hemophilus influenzae type b vaccine, hib vaccine, Haemophilus influenzae Type b vaccine (product), Haemophilus influenzae Type b vaccine (substance), Haemophilus influenzae type b vaccine (substance), Haemophilus influenzae type b vaccine, HIB - Haemophilus influenzae Type B vaccine, Haemophilus influenzae Type b vaccine
Spanish vacuna anti-Haemophilus influenzae tipo b (producto), vacuna anti-Haemophilus influenzae tipo b, vacuna anti-Haemophilus influenzae tipo b (sustancia)